Genome-wide association studies have identified several common single nucleotide polymorphisms (SNP) associated with an increased risk of colorectal cancer (CRC), although they have failed to identify any recessively acting alleles that contribute to disease risk. However, two recent studies have suggested that inbreeding and runs of homozygosity (ROH) increase the risk of developing cancer, perhaps by exposing recessive alleles as a result of autozygosity. To examine these results in a relatively large case-control series, we analyzed samples from a cohort in the United Kingdom comprising 921 colorectal tumor cases and 929 controls. Individuals were genotyped using a 550,000 tagging SNP panel. Additionally, we identified from these SNPs a set of f30,000 SNPs in low pairwise linkage disequilibrium. To determine whether homozygosity was associated with CRC, we performed multiple tests to assess homozygosity at individual SNPs and ROHs in cases and controls. No association was found between CRC and (i) homozygosity at any individual SNP, (ii) overall homozygosity or level of inbreeding, (iii) total length or number of ROHs per individual, or (iv) a ROH at any particular genomic location. In conclusion, our results from a large case-control series do not replicate those of previous studies and suggest that homozygosity/autozygosity is not a major risk factor for CRC in an outbred population.
Introduction
Recent genome-wide association studies (GWAS) have identified several common single nucleotide polymorphisms (SNP) that are associated with modestly increased risks of colorectal cancer (CRC; refs. 1-4). However, even when the effects of these SNPs are added to those of the known, high-penetrance Mendelian predisposition genes, only a minority of the total familial aggregation of CRC can be explained. The remaining familial risk might be explained by further, unidentified SNPs, copy number variants (CNV), or rare alleles with modest effects.
It is notable that, to date, the great majority of the CRC predisposition genes act in a codominant fashion and GWASs have found no good evidence of recessively acting alleles (5) . Although this may reflect disease biology, it may also result from the GWASs having suboptimal ability to detect recessive disease alleles. Clues that cancer might sometimes have a recessive basis have come from several case reports, such as that of Lebel and colleagues (6) , who found in a 1,000-strong kindred that CRC was present in 14 members, of whom 13 were the product of consanguineous relationships. Cancer risk has also been reported to be increased in some inbred populations (7) , although the underlying reasons for these observations have been unclear. Conversely, there are reports of inbreeding actually reducing cancer risk, such as that from a case-control study of a population from the United Arab Emirates (8) . The effects of inbreeding on the risk of complex diseases may, therefore, be population-dependent and/or disease-dependent.
Recently, Assié and colleagues (9) studied 385 patients of Northern/Western European ancestry with one of three different solid tumors (breast, prostate, and head and neck carcinomas) by whole-genome loss of heterozygosity analysis using 345 microsatellite markers. The authors reported a significant increase in the frequency of homozygosity in pooled cases compared with database controls from the Cooperative Human Linkage Center study (10) . In a different study based on the Affymetrix Xba I 50 K SNP array, Bacolod and colleagues (11) analyzed homozygosity specifically in relation to the risk of CRC. By focusing on runs of homozygosity (ROH) that spanned at least 4 Mb and contained a minimum of 50 SNPs, Bacolod and colleagues found that CRC cases harbored significantly more homozygous regions than did controls. An exact calculation of the probabilities of being truly homozygous in 5 Mb sliding windows confirmed greater homozygosity in cases than controls. These findings led the same group to propose an important role for homozygous regions in cancer progression and chromosomal instability (12) .
The studies of Assié and colleagues (9) and Bacolod and colleagues (11) support the hypothesis that there exist multiple, recessive, cancer-predisposing loci, but that these cannot readily be detected using the GWAS type of approach. The reasons for this may be that relative risks per locus are too low and/or that the disease-associated variants are not in strong linkage disequilibrium (LD) with tagSNPs, perhaps because of low allele frequencies. In order to address this issue further, we have examined the frequencies of homozygosity, both at individual SNPs and within ROH regions, in a relatively large series of CRC cases and controls. Because no established method exists for comparing homozygosity in cases and controls, we have used several different methods of testing in our analysis.
females) who were spouses or partners unaffected by cancer and without a personal family history (to second-degree relative level) of colorectal neoplasia. These individuals were recruited through the Colorectal Tumor Gene Identification (CORGI) consortium (4). All cases had at least one first-degree relative affected by CRC and one or more of the following phenotypes: CRC at age 75 or less; any colorectal adenoma at age 45 or less; z3 colorectal adenomas at age 75 or less; or a large (>1 cm diameter) or aggressive (villous and/or severely dysplastic) adenoma at age 75 or less. This case-control series has been used in our GWASs to identify CRC susceptibility SNPs (1, 3, 4, 13) and some genotyping results have been reported in these articles in which CRC predisposition SNPs have been reported. The replication phase (VQ58) was undertaken using a further set of 1,214 CRC cases (770 males and 444 females; mean age of diagnosis, 62.4 years; SD F 10.7) from the VICTOR/QUASAR2 clinical trials of Dukes stage B/C CRCs and 1,435 population controls (628 males and 807 females) from the United Kingdom 1958 Birth Cohort ( further details of samples sets available in ref. 5). We have previously confirmed an absence of systematic genetic differences between cases and controls and shown no evidence of population stratification in these sample sets (1, 3, 4, 13) .
Genotyping. DNA was extracted from samples using conventional methods and quantified using the PicoGreen technique (Invitrogen). SNP genotyping was initially performed using the Illumina Infinium Hap550 arrays, comprising 550,163 tagSNPs. We considered that a DNA sample had failed if it did not generate a genotype for at least 95% of the loci. Similarly, a SNP was considered a failure if <95% of DNA samples generated a genotype at the locus. To ensure the quality of genotyping, a series of duplicate samples were genotyped on the same arrays. The genotyping call rate was 99.84%. To identify samples showing relatedness, identity by state values were calculated for pairs of individuals. For any pair with >80% identical SNP genotypes, we removed the sample with the lower call rate from the analysis. We restricted our data analysis to the autosomal SNPs on the array. We excluded SNPs on the basis of deviation from Hardy-Weinberg equilibrium using a threshold of P < 1 Â 10 À5 in either the cases or controls. We also removed SNPs with a minor allele frequency of <0.05 in our samples. This left 486,303 SNPs in the full ''500 K panel.' ' We had concerns that use of correlated SNPs in pairwise LD might, in effect, lead to double counting of some data points, thus causing exaggeration of small random differences and hence production of falsepositive results in statistical tests. For some analyses, therefore, we removed SNPs in LD from the 500 K panel using the pairwise LD SNP pruning function in PLINK with r 2 < 0.1. The remaining 30,307 SNPs formed a panel of SNPs in approximate linkage equilibrium (the ''low-LD panel''). Some SNPs were imputed using the program IMPUTE (14) , available at the University of Oxford web site. 3 The program was run according to the guidelines there. In order to maintain genotype confidence, imputed genotypes with a probability of <90% were rejected from the analysis.
Statistical analysis. In general, statistical analyses were performed using packages available in R (version 2.7.0). Copy number variations were detected using QuantiSNP (15) . We detected ROHs using PLINK v1.05 (16) . 4 The PLINK ROH tool (''homozyg'' command) moves a sliding window of 50 SNPs across the entire genome. Then, based on the set thresholds, it is determined at each position whether the window meets the required level of homozygosity. For each SNP, the proportion of homozygous windows that overlaps the SNPs position is calculated and used to determine whether the ROH meets the minimum criteria (number of SNPs or size). The guidelines on the web site for the ROH tool state that this analysis should be performed on SNP panels that are in approximate linkage equilibrium, in order to improve the detection of ROHs that represent autozygosity and not just chance, although we undertook the analysis using both the 500 K and low-LD panel. To allow for genotyping error or other sources of artificial heterozygosity, such as paralogous sequences, within a stretch of truly homozygous SNPs and, hence, to prevent underestimating the number and size of ROHs, 2% heterozygous SNPs were allowed in each window. For the 500 K SNP panel, we left the remaining PLINK ROH tool options set to the default values (including allowing five missing calls per window), except that we varied the parameters for ''homozyg-snp'' (to set the minimum number of SNPs) and ''homozyg-kb'' (to set the minimum size) according to our heuristic preferences for defining the ROH. However, owing to the much lower density of SNPs in the low-LD panel, we removed the limitations on the maximum distance between SNPs (''homozyg-gap'' option) and the minimum density of SNPs (the ''homozyg-density'' option) for the analysis. The ''homozyg-group'' option was used to produce a file of the overlapping ROH regions separated into pools containing the number of cases and controls carrying the ROH. We deemed that pools with more than five samples were recurrent ROHs. A consensus SNP set representing the minimal overlapping region across all samples in the pool was used to define the recurrent ROH regions. The inbreeding coefficient (F) was calculated for each individual using a function in PLINK (''het''). This function uses the equation: 
Results
We decided to analyze associations between homozygosity and CRC in two ways. First, we examined the frequency of homozygotes by individual SNP. Second, we examined ROHs-potentially reflecting autozygosity-that extended over tens or hundreds of SNPs. In general, analyses were performed using both the 500 K and the low-LD SNP panels.
Genome-wide assessment of associations between homozygosity at individual SNPs and CRC risk. We initially tested association between homozygosity (whether for the major or minor allele) and CRC risk on a SNP-by-SNP basis in the 500 K panel in the CORGI sample series. Details of the results for the 35 SNPs with P homoz < 1 Â 10 À4 are shown in Table 1 . No SNP reached globally significant association (considered to be P homoz < 10 À7 , using the widely accepted threshold for GWASs). The most strongly associated SNP was rs17062732 [chr13:41,495,284 bases; P homoz = 5.9 Â 10
À6
; odds ratio (OR), 1.61]. We undertook validation of rs17062732 and all SNPs with P < 1 Â 10 À4 in the VQ58 cohort. Ten of these SNPs, including rs17062732, were not genotyped in the cases of the VQ58 and so analysis was performed using imputed data. However, in all cases, the strength of association after MantelHaenszel meta-analysis was weaker than in the original CORGI series (Table 1) . Specifically, there was no good evidence of an association between homozygosity at rs17062732 and CRC risk (P homoz = 0.004; OR, 1.21, fixed effects model). No other SNP achieved a globally significant association (Table 1) , the most strongly associated SNP after the meta-analysis being rs6029910 (chr2:40,042,498, P homoz = 2.86 Â 10 À5 ; OR, 0.78, fixed effects model). Although no individual SNP was significantly overrepresented as a homozygote in cases compared with controls, we wondered whether we could detect weaker effects of homozygosity at multiple loci by performing analyses across the whole set of SNPs. Initially, we undertook a simple analysis of the total numbers of homozygous SNPs in cases and controls, without regard to minor allele frequency. For the SNPs from the 500 K panel, the mean number of homozygous SNPs in cases was 315,644 (median = 315,779; SD = 2,059), compared with 315,583 (median = 315,615; SD = 1,781) in controls (P = 0.029, Wilcoxon test). However, this borderline association was not confirmed when we repeated the analysis using the low-LD panel, in which cases and controls had very similar numbers of homozygous SNPs, specifically means of 21,499 (median = 21,506; SD = 126) and 21,496 (median = 21,501; SD = 111), respectively (P = 0.397, Wilcoxon test).
Next, we formally calculated the inbreeding coefficient (F) for all samples using the low-LD SNP set. The calculated value of F for each sample is given in Supplementary Tables S1 and S2. The means (SDs) for F in cases and controls were 0.00135 (0.012) and 0.00101 (0.012), respectively, not significantly different from each other (P = 0.54, t test). Therefore, there was no evidence to suggest that cases were, in general, more inbred than controls.
Analysis of ROHs in cases and controls. The existence of LD blocks means that relatively short ROHs, from tens to hundreds of kilobases, are common across the genome (17) . Evidently, most of these regions probably do not result from true autozygosity. We therefore set thresholds to define an ROH based on genomic regions in which either a minimum number of consecutive, nonmissing SNPs was homozygous (allowing for miscalls), or homozygosity extended for a minimum length along the chromosome. We decided to measure ROHs per individual in terms of their total length (that is, the sum of the lengths of the ROHs found in each person) because this may provide a better measure of autozygosity than the total number of ROHs. For example, with a threshold ROH size of 4 Mb, the latter method would twice score two ROHs of 4 Mb, but only score a single region of 8 Mb once; in terms of indicating autozygosity, however, a single 8-Mb region would be at least as important as two 4-Mb regions.
In order to provide a comparison with the work of Bacolod and colleagues (11), we initially analyzed ROHs that were z50 SNPs 
Genotyped ----------------------------------------------------------------------
NOTE: P homoz was calculated using a simple 2 Â 2 m 2 1 test based on the number of homozygotes and heterozygotes at each SNP in cases and controls. The sample set used had >90% power to detect the effects of a homozygosity associated with an OR of 1.5 at P = 10
À5
, prior to the replication phase.
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Cancer Res 2009; 69: (18 in length using the 500 K SNP panel (Table 2 ). Every individual had at least 100 ROHs and the mean number of these regions per individual was approximately 500. There was no evidence of an association between the total ROH size in each individual and CRC (P = 0.269, Wilcoxon test; Table 2 ). To determine whether this result was robust, we repeated the analysis using a number of different criteria to define a ROH (z30 SNPs, z40 SNPs, z60 SNPs, z2 Mb, z4 Mb, and z10 Mb). Again, no evidence was found for an association between total size of the ROHs in each individual and CRC (Table 2) . We then repeated the analysis in the low-LD SNP panel using the same ROHdefining criteria as above. The majority of individuals carried no homozygous regions under any of the criteria and those regions that were detected were typically large (>2 Mb in size). Analysis of the total size of ROHs in each individual determined again that there was no significant difference between cases and controls ( Table 2 ). The total sizes of ROHs detected in each person using the 500 K and low-LD SNP panel are summarized in Supplementary Figs . S1 and S2 and detailed in Supplementary Tables S1 and S2, respectively.
In order to provide a further comparison between our results and those of Bacolod and colleagues (11), we calculated the frequencies of cases and controls in which we detected one or more ROHs of z4 Mb. Using the 500 K SNP panel, 159 of 921 (17%) cases and 142 of 929 (15%) controls had ROHs (P = 0.14, Fisher's exact test). For the low-LD panel, 8 of 921 (0.87%) cases and 8 of 929 (0.86%) controls had ROHs of z4 Mb (P = 0.59, Fisher's exact test). We thus failed to detect the marked difference between cases (62.2%) and controls (35.6% and 28.8%) that was seen in Bacolod and colleagues' study.
The locations of the ROHs defined using the z50 SNPs and z4 Mb criteria are shown in Fig. 1 for the low-LD panel and in Supplementary Fig. S3 for the 500 K panel (z4 Mb criterion). The five longest homozygous regions (Fig. 1) were derived from just two individuals (case 1053H10 and control 1049G06). These individuals were known to have somewhat higher levels of inbreeding than the average (Supplementary Tables S1 and S2 ; Supplementary Fig. S1 ), although their family histories were unremarkable and showed no evidence of consanguineous marriage. Several long ROHs straddled centromeres, suggesting the possibility of underlying pericentric inversions. Few ROHs involved telomeres, chromosome arms or whole chromosomes, suggesting that uniparental isodisomy was uncommon (see below). In the 500 K SNP panel ( Supplementary Fig. S3 ), relatively frequent ROHs were found at chromosome 11p11 and 6p22.1. These correspond to regions of long-range LD known to exist in European populations (18) .
Recurrent regions of homozygosity. Although most of the regions of homozygosity examined thus far were individually uncommon, some occurred in >10% of cases or controls when assessed using the 500 K panel. We therefore addressed whether any of these specific, relatively common homozygous regions was associated with CRC risk. Using ROHs with z1 Mb of consecutive homozygous SNPs detected in the 500 K panel, we searched for Table 2 . Total size of ROHs per individual in cases and controls as identified using the 500 K and the low-LD SNP panels NOTE: ROHs were defined using each of the SNP number or size criteria shown. The mean, median, and range data across the set of cases or controls were determined by adding the sizes of all ROHs in each individual. For each ROH size criterion, the distribution of the data in individuals is given in Supplementary Figs . S1 and S2. The P values (Wilcoxon rank sum test) were derived from a comparison of total ROH size between cases (n = 921) and controls (n = 929). Note that the total ROH size in the 500 K panel is much larger than that of the low-LD panel, especially when ROHs are defined by the number of SNPs, simply as a result of the higher density of SNPs in the former. The final column shows the mean size of each ROH detected ( for cases and controls combined). Research.
on July 24, 2017. © 2009 American Association for Cancer cancerres.aacrjournals.org Downloaded from minimal overlapping ROH regions that were found in more than five individuals (cases and/or controls). This resulted in a total of 3,478 ROHs that met the inclusion criteria. After taking multiple testing into account, none reached global significance for an association between homozygosity for any region and CRC risk. The most strongly associated regions were at adjacent sites on chromosome 2 at f160 Mb (Supplementary Table S3 ), although these ROHs were actually more common in controls than cases. We checked haplotype frequencies within each of the 20 recurrent ROHs associated with P < 0.01 (Supplementary Table S3 ), but found no evidence of overrepresentation of a particular haplotype in any case (P > 0.6 for all, Fisher's exact test). When the analysis was repeated with the low-LD panel, 99 common ROH regions were detected. Again, none of these regions showed any evidence of association with disease (P > 0.12 for all; Supplementary Table S4) .
Are apparently homozygous regions really hemizygous? Homozygous regions might result from chance, autozygosity, uniparental isodisomy, or hemizygosity. To determine whether the common homozygous regions were actually hemizygous CNVs, the positions of the common ROHs were compared with those of CNVs identified using QuantiSNP. 5 We searched for CNVs that covered at least 90% of the detected ROH. However, none of the common ROHs detected, in either the 500 K or the low-LD panel, could be explained by a CNV (details not shown).
Discussion
Recent studies (9, 11) have reported an increased frequency of homozygous microsatellites or ROHs in cancer cases than controls. Whether explicitly or implicitly, these studies have been interpreted as being consistent with previous reports that show cancer as more prevalent in inbred populations. The neatness of an explanation for increased cancer risk based on the frequency of homozygous regions and consanguinity is attractive, and has formed the basis of a new model of cancer progression (12) . However, various criticisms can be made of these studies. First, the observation of increased cancer risk in inbred groups has often been reported after studying a relatively small number of individuals in an isolated community or a single large family with a high level of inbreeding. Thus, the relevance of inbreeding to the population risk of cancer is unclear and inbreeding and founder effects may be confounded. Second, sample sizes in the molecular studies (9, 11) have generally been small and, crucially, case and control groups in these analyses have been ethnically heterogeneous and/or unmatched. Third, it is unclear whether LD between polymorphic markers may have caused test statistics to be inflated: for example, only 11,142 out of 58,136 SNPs remain once those in LD (r 2 > 0.1) are removed from the Affymetrix 50 K Xba I SNP panel used in the analysis of Bacolod and colleagues (11) . Fourth, effects of age or gender differences in recombination may have influenced results, although we found no effect of these variables in this study (details not shown). Fifth, the optimum study design for assessing the effects of homozygosity/autozygosity on disease risk is not yet clear: for example, in most Western populations, inbreeding levels are probably too low to produce much reliably detectable autozygosity and control for covariates in the few individuals who do show detectable autozygosity is extremely difficult.
We have tried to address some of these issues by analyzing a relatively large set of CRC cases and controls which have been genotyped at several hundred thousand SNPs genome-wide. This same sample series has robustly identified 10 CRC predisposition SNPs. All of the individuals in our study were from an apparently panmictic population with no evidence of stratification (4). Our analyses have been undertaken both including and excluding SNPs in notable pairwise LD. Overall, evidence for an association between homozygosity and CRC risk was very limited. We did not find cases to be significantly more or less inbred than controls. Furthermore, our ROH analysis provided no evidence for an association between total ROH size per individual and increased risk of CRC, under any of several size criteria, using either the 500 K or the low-LD SNP panel.
We conclude that there is no convincing evidence to show that levels of measured homozygosity-whatever their origins from autozygosity, uniparental isodisomy, or hemizygosity-are associated with an increased risk of CRC in a predominantly outbred population, such as that from the United Kingdom. This analysis does not exclude the effect of recessive alleles, whatever their penetrances, in this population or of autozygosity in more inbred groups. However, it seems unlikely that there exist large numbers of recessive alleles that predispose to CRC and that are unmasked by autozygosity in most white European populations.
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